Quanterix launches novel p-Tau 205 and p-Tau 212 assays to advance Alzheimer’s research at AAIC
Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research
31 Jul 2025Product news
Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, has announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration. The announcement comes alongside Quanterix’s robust presence at the Alzheimer’s Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa® technology.
These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer’s disease. Developed on Quanterix’s ultra-sensitive Simoa® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers.
Quanterix’s growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside.
“The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer’s,” said Masoud Toloue, PhD, CEO of Quanterix. “Combined with the recent integration of Akoya’s spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we’re advancing the future of precision diagnostics across neurology, oncology, and immunology.”
The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix’s in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia.